Bavarian Nordic A/S (BVNRY)
- Previous Close
7.15 - Open
7.15 - Bid --
- Ask --
- Day's Range
7.15 - 7.15 - 52 Week Range
5.95 - 10.65 - Volume
13 - Avg. Volume
5,293 - Market Cap (intraday)
1.672B - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
7.86 - EPS (TTM)
0.91 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Mar 27, 2020
- 1y Target Est
--
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
www.bavarian-nordic.comRecent News: BVNRY
Performance Overview: BVNRY
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BVNRY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BVNRY
Valuation Measures
Market Cap
1.67B
Enterprise Value
1.42B
Trailing P/E
7.82
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.63
Price/Book (mrq)
1.13
Enterprise Value/Revenue
0.20
Enterprise Value/EBITDA
0.67
Financial Highlights
Profitability and Income Statement
Profit Margin
20.89%
Return on Assets (ttm)
10.19%
Return on Equity (ttm)
16.87%
Revenue (ttm)
7.06B
Net Income Avi to Common (ttm)
1.48B
Diluted EPS (ttm)
0.91
Balance Sheet and Cash Flow
Total Cash (mrq)
1.87B
Total Debt/Equity (mrq)
1.40%
Levered Free Cash Flow (ttm)
688.43M
Company Insights: BVNRY
BVNRY does not have Company Insights